Virtu KCG Holdings’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Virtu KCG Holdings’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-72,989	Closed	-$309K	–	4189
2016 Q3	$309K	Buy	72,989 +53,438	+273%	+$173K	0.01%	1897
2016 Q2	$47K	Buy	+19,551	New	+$70.7K	﹤0.01%	2692
2016 Q1	–	Sell	-19,199	Closed	-$75K	–	4255
2015 Q4	$75K	Buy	+19,199	New	+$88.5K	﹤0.01%	3072
2015 Q1	–	Sell	-28,023	Closed	-$91K	–	4520
2014 Q4	$91K	Buy	+28,023	New	+$113K	﹤0.01%	3267

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu KCG Holdings's AST Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2016, closing a stake of 72,989 shares — an estimated $309K sold.

Virtu KCG Holdings first reported a position in AST in Q4 2014 and held it in 4 quarters. The position peaked at $309K in Q3 2016. 66 funds tracked by Wall St. Rank hold AST as of Q4 2016.

Virtu KCG Holdings reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2016 after selling out during the quarter.
Virtu KCG Holdings sold 72,989 Asterias Biotherapeutics Inc. Series A shares in Q4 2016, an estimated $309K.
Virtu KCG Holdings first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 4 quarters.
Virtu KCG Holdings's Asterias Biotherapeutics Inc. Series A position peaked at $309K in Q3 2016.
66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.